PhD & post-graduate Doctor of Medicine degree (MD) in Nuclear Medicine (2015), Chinese Academy of Medical Sciences & Peking Union Medical College, China
Nuclear Medicine Physician (2015-2017), Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, China, and Nuclear Medicine Clinical & Research Fellow (2018-2020), THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Germany
Editorial Board Member for Clinical Nuclear Medicine (IF=10.6)
Research interest: integrated diagnosis and treatment of peptide receptor radionuclide therapy (PRRT), development and clinical translation research of radionuclide drug conjugates (RDC) for molecular imaging therapy, and precision oncology research of radiopharmaceuticals.
Engaged in drug translational and clinical application of Ga-68/Lu-177/Ac-225 labelled radiopharmaceuticals for over 10 years.
Completed clinical translational research on more than 20 positron emission tomography (PET) imaging agents and Lu-177-Missing labeled radiopharmaceuticals, and conducted more than 10 First-in-Human translational research studies.
Published more than 60 peer-reviewed articles on Journal of Nuclear Medicine (JNM), Accounts of Chemical Research (ACR), Nature Reviews Bioengineering, Theranostics, Bioengineering & Translational Medicine, European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI), Clinical Nuclear Medicine (CNM), etc.
Received the Thomas O’Dorisio Young Investigator Award in Germany, NETs honors, one of TOP thirty early career professionals who stand out as "Ones to Watch" in 2019 by the Society of Nuclear Medicine and Molecular Imaging, Majd-Gilday Investigator Award and the Young Professionals Committee Prize from SNMMI.
